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Introduction
The production of pooled platelet concentrates (PPCs), aphere-
sis platelet concentrates (APCs), red blood cell concentrates 
(RBCCs), fresh frozen plasma (FFP), and other blood components 
(e.g. blood coagulation factors) is interlinked. Changes in the pro-
duction of one blood component may have consequences for the 
availability and quality of other components.
Data for platelet concentrate (PC) production in France, Germany, 
Switzerland, and the UK show that so far a significant percentage of 
produced PCs consists of apheresis platelets (table 1). Clinical guide-
lines do not differentiate between the application of PPCs or APCs 
except in patients with immune-mediated transfusion refractoriness 
and fetal and neonatal alloimmune thrombocytopenia (FNAIT). For 
those patients, single-donor apheresis platelets matched for human 
leukocyte antigens (HLA) and/or human platelet antigens (HPA) are 
recommended [1, 2]. The incidence of FNAIT is one in 1,000 live 
births [3, 4]. Studies focusing on hemato-oncological patients indicate 
that platelet refractoriness varies widely (7–34%). The major cause for 
inadequate platelet increment in this patient collective originates from 
non-immunologic reasons like fever, infectious diseases, and sepsis 
with disseminated intravascular coagulation. Moreover, splenomeg-
aly, bone marrow involvement, or cytoreductive chemotherapy also 
contributes to inferior transfusion success. Immunological causes for 
platelet refractoriness in hemato-oncology derive mostly from HLA 
alloimmunization which may be due to prior transfusions as well as 
prior pregnancy in female patients [5–7].
The fact that APCs generally are more costly compared to PPCs 
accelerates discussions around decreases in the production and 
supply of APCs. In 2014, the National Health Service Blood and 
Transplant (NHSBT) has released new recommendations for a re-
duction of apheresis production of platelets from approximately 
80% to 60% of overall platelet provision by the end of 2015/2016 [8, 
9]. A clinical model was developed indicating that only about 40% 
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Summary
Background: In Germany, about 60% of all produced 
platelet concentrates (PCs) are apheresis PCs (APCs). On-
going discussions on APC reimbursement and costs 
might lead to a potential shift in pooled PC (PPC)/APC pro-
duction. Objective of this analysis was to build a compre-
hensive model from the societal perspective to evaluate 
consequences associated with shifts in platelet supply 
and demand. Methods: Literature search, desktop re-
searches on platelet supply and demand. Model calcula-
tions, time horizon one year: model input from the Paul-
Ehrlich-Institute, data 2013. Base case: 19.2% of annual 
whole blood donations (WBDs) were used for production 
of 38.5% PPCs, decay of 46,218 PCs (8.0%). Scenarios cal-
culated: variation in PPC proportion of 10–100%. Results: 
Base case: during PPC production 41,957–83,913 red 
blood cell concentrates (RBCCs) are estimated to be lost, 
which corresponds to 1–2% of annual RBCCs in Germany. 
Scenarios were calculated for a production of 60–100% 
PPCs: loss is estimated to be 1.5–5.0% of annual RBCCs 
(65,430–218,099), decay 54,189–69,022 PCs (9.4–12.0%). 
Conclusion: Production of different blood components is 
interlinked and sensitive to unidimensional decisions. In-
creasing PPC proportion has negative impact on the RBCC 
production and on the antigen-matched APC donor pool. 
Completion of the model calculations to predict the opti-
mal PPC/APC proportion would require evidence on the 
number of refractory patients, donor pool sizes, and inci-
dences of diseases requiring platelet transfusions.
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single-donor apheresis platelets will be needed to satisfy current 
patient demands for the following specific patients: i) neonates and 
pediatrics and ii) patients requiring HLA/HPA matched platelets. 
The model is financially driven and should help to reduce costs 
and to implement platelet-additive solution for all PCs. Basis of the 
model is the assumption that there is no difference in clinical effi-
cacy between apheresis or buffy coat-pooled platelets [8].
In Germany, health insurance companies are increasingly ask-
ing for a rationale when single-donor APCs instead of the less 
costly buffy coat PPCs are provided. This has become evident in a 
recent decision of the Federal Social Court (March 10, 2015; refer-
ence number B 1 KR 2/15 R). In this case, the statutory health in-
surance did not have to pay for the additional charge for APC 
transfusion in a cardiac surgery patient [10, 11]. One of the major 
consequences of a decreasing proportion of APCs used will be that 
the donor pool for APCs will decline. For Germany in 2010, a total 
of 36,791 multiple apheresis donors with on average 5 apheresis 
donations/year were reported [12]. Matching patients with the ap-
propriate HLA/HPA-typed platelets in the future will only be feasi-
ble with a sufficiently large pool of apheresis donors.
The focus of this paper is to analyze consequences associated 
with potential shifts in the supply and use of PPCs and APCs in 
Germany based on model calculations. 
Material and Methods
Model
A model was designed to identify the parameters which influence future PC 
supply and demand and the proportion of PPCs and APCs required (fig.  1). 
German epidemiological data on PC demand, various aspects of PC produc-
tion, and the special demand of specific patients for single-donor apheresis 
platelets were searched for by literature and desktop researches. Included issues 
of future PC production were amongst others donor availability, whole blood 
donations (WBDs) and apheresis donations, losses of WBDs due to buffy coat 
production, the size of the donor pool needed to provide sufficient HLA/HPA-
typed platelets for specific patients, and rates of PC decay.
Model calculations from the societal perspective were conducted based on 
data from literature and desktop researches. An exemplary 1-year period was 
selected. The influence of the proportion in PPC and APC production on losses 
of quality and quantity of erythrocytes during buffy coat separation, on total PC 
decay at the producer, and on the availability of HLA/HPA typed donors was 
estimated.
Table 1. Platelet production in European countries
Country Proportion of PPC / APC production, number (%) Changes in total  
PC production  
2012–2013, %
Population-related 




pooled PCs apheresis PCs pooled PCs apheresis PCs
France 154,955 (51.5) 145,728 (48.5) 158,173 (51.6) 148,069 (48.4) +1.8 4.81 [30–32]
Germany 226,206 (38.4) 362,709 (61.6) 222,228 (38.5) 355,365 (61.5) –1.9 7.15 [13, 33]
Switzerland  11,650 (34.0)  22,615 (66.0)  12,162 (35.0) 22,588 (65.0) +1.4 4.34 [34–36]
UK*  40,863 (14.7) 237,212 (85.3)  55,121 (19.3) 230,171 (80.7) +2.6 4.45 [37-39]
*For the UK, data were from National Health Service Blood and Transplant (NHSBT) only (England and North Wales).
Proportion of 
PPCs and APCs 
required 
PC Production 
• Donor availability 
• Number of WBDs 
• Number of apheresis donations 
• Losses of RBCs due to buffy coat production 
• Donor pool for HLA/HPA-typed apheresis platelets 
• Decay of pooled PCs 
• Decay of apheresis PCs 
Demand of specific patients for APCs 
• Alloimmunized patients with platelet refractoriness 
• FNAIT 
• Pediatrics 
• Multitransfused leukemia patients 
• Allogeneic HSCT recipients 
 
PC Demand 
Fig. 1. Model: influ-
ences on the proportion 
of PPCs and APCs re-
quired in the future. Re-
liable models of future 
PC supply and demand 
have to consider epide-
miological data on PC 
demand, various aspects 
of PC production and 
the special demand of 
specific patients for sin-
gle donor APCs. As-
pects of future PC pro-
duction are donor avail-
ability, WBDs and 
apheresis donations, 
losses of WBDs due to 
buffy coat production 
and subsequently 
RBCCs, the size of the donor pool needed to provide sufficient HLA/HPA-typed platelets for specific patients, and the decay of PCs at the producer. Aspects of the 
demand of specific patients for APCs are the epidemiology of alloimmunization and FNAIT, the demand in pediatrics, and possible advantages of single-donor 
APCs for hemato- oncological patients.
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Model Input
PubMed was searched for data on PC supply and demand, on PPC and APC 
production and transfusion, on platelet refractoriness, on FNAIT, on HLA 
matching, and on platelet transfusions in hemato-oncological patients. The fol-
lowing searches were conducted: (‘Platelet Transfusion/statistics and numerical 
data’[Mesh] OR ‘Platelet Transfusion/therapeutic use’[Mesh] OR ‘Platelet 
Transfusion/therapy’[Mesh] OR ‘Platelet Transfusion/utilization’[Mesh]), 
‘Blood Donors’[Mesh] AND ‘Germany’[Mesh], ‘Thrombocytopenia, Neonatal 
Alloimmune’[Mesh], ‘Platelet Transfusion’[Mesh] AND ‘Immunosup-
pression’[Mesh], ‘Platelet Transfusion’[Mesh] AND ‘Leukemia’[Mesh]. In addi-
tion, free search terms, e.g. ‘pooled platelets’ AND ‘apheresis platelets’ as well as 
‘hematological malignancies’ AND ‘platelet transfusion’, were applied. Each 
search was done for the last 10 years. Citations of identified journal articles 
were searched for further relevant publications. Desktop researches, predomi-
nantly internet searches for existing data, were performed. Model input data 
identified for calculations: Data from the Paul-Ehrlich-Institute (PEI) for the 
year 2013 on the production of PPCs and APCs in Germany were used [13]. 
Estimated losses of erythrocytes during production of PPCs were taken from 
the literature [14].
Assumptions
The following assumptions were made: i) There is no difference reported 
between PPCs and APCs concerning clinical efficacy [1, 2, 8, 15]. ii) Four 
WBDs are needed for the production of 4 buffy coats to obtain 1 PPC [15–17]. 
iii) During buffy coat-derived PPC production from WBDs, a proportion of 
erythrocytes is lost or damaged. The estimated loss of erythrocytes amounts to 
5–10% of the WBDs used [14]. WBDs are used for the production of RBCCs. In 
Germany, the yield of annual RBCCs from the annual WBDs in 2013 was 94.4% 
(table 2). Estimated losses in WBDs are converted in estimated final losses of 
RBCCs. iv) The decay rate at the producer for PPCs and APCs remains approx-
imately stable as in 2013 (table 2) [13] v) APCs will continue to be needed for 
neonates, pediatric patients, and for patients requiring HLA/HPA matched 
platelets [2–4, 6, 7].
Base Case
The model calculations for the base case describe the current situation for 
PPC/APC production in Germany. Base case calculations are based on data 
from the PEI for the year 2013 (table 2) [13].
Scenarios
Different scenarios were calculated. Proportions of PPCs were assumed to 
be 10% up to 100% of total PCs produced using the data from the PEI for the 
year 2013 [13].
Model Output
Model output is expressed as number of WBDs needed for the production 
of the corresponding amounts of PPCs, as percentage of annual WBDs used for 
production of PPCs, as the estimated number of WBDs lost annually due to the 
production of PPCs, as the estimated number of the calculated corresponding 
RBCCs lost annually, as the estimated percentage of annual RBCCs lost, and as 
the estimated decay of PCs at the producer in number of PCs and in percent of 
total PCs produced annually. The expected impact of changes in the proportion 
of PPCs produced on the pool of HLA/HPA-typed apheresis donors is 
addressed.
Results
In 2013, a total of 888,912 WBDs were used to produce 222,228 
buffy coat-derived PPCs in Germany. This corresponds to 19.2% of 
annual WBDs. The losses of erythrocytes in these WBDs used for 
buffy coat PPC production were estimated to amount to 44,446–
88,891 WBDs. This corresponds to 41,957–83,913 RBCCs, which is 
an estimated percentage of annual RBCCs lost in Germany of ap-
proximately 1–2%.
Calculations for different scenarios with a proportion of 10% up 
to 100% PPCs produced were conducted (table 3). Up to a propor-
tion of 20% PPCs, no more than 10% of annual WBDs are used for 
buffy coat PPC production. The estimated percentage of annual 
RBCCs lost is 1% or below. The total decay of PCs at the producer 
is below 40,000 PCs (<7% of total PCs produced). With 60% PPCs 
produced, the estimated percentage of annual RBCCs lost increases 
up to 3.0%. This corresponds to an estimated number of more than 
130,000 RBCCs lost annually. A total of 54,189 PCs (9.4% of total 
PCs produced) are lost due to decay at the producer. HLA/HPA-
typed apheresis donors are reduced. With a change to 100% PPCs, 
overall 50% of annual WBDs have to be used for buffy coat pro-
duction. This leads to an estimated percentage up to 5% of annual 
RBCCs lost and corresponds to an estimated number of more than 
200,000 RBCCs lost annually. The number of PCs lost due to decay 
at the producer increases up to 69,022 (11.95% of total PCs pro-
duced). In addition, the pool of HLA/HPA-typed apheresis donors 
disappears.
Discussion
Available data for Germany indicate that both types of platelet 
concentrates, buffy coat-derived PPCs as well as single-donor 
APCs, are needed to meet the requirements of a flexible and suffi-
cient supply for all kinds of patients [16, 17]. Likewise, in 2011 the 
German Society for Transfusion Medicine and Immune Hematol-
ogy already recommended to provide both types of platelets to 
avoid the hazards of critical shortage in platelet supply [18]. In this 
context extensive elaborations have been published on different as-
pects of the PC supply in Germany, e.g., on the quality of APCs 
compared to PPCs, on reimbursement, on the advantages of decen-
tralized small apheresis donation units close to the hospital, or on 
the general possibility to shift the total supply to APCs but not to 
PPCs [11, 15–17, 19–21]. Still the question on the optimal propor-
tion of PPC/APC production for Germany has not been answered.
Whole blood donations
RBCs total PCs pooled PCs apheresis PCs
Production, n (%)  4,371,743 (100) 577,593 (100) 222,228 (38.5) 355,365 (61.5)
Decay at the producer, n (%) 98,945 (2.26)  46,218 (8.00)  26,552 (11.95)  19,666 (5.53)
*Data are from the Paul Ehrlich Institute (PEI) 2013 [13]. Total registered 2013: 4,631,290.
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Shifting the Supply from APCs to PPCs
Ongoing discussions on increased cost of APCs over PPCs 
might lead to a potential shift in APC supply towards PPCs. In 
2013, the proportion of APCs produced was 61.5% in Germany, 
80.7% in the UK, and 48.4% in France (table 1). Mainly driven by 
financial arguments the NHSBT has recommended in 2014 to re-
duce APC production stepwise to 60% of the overall platelet provi-
sion by the end of 2015/2016. In the UK, it has been estimated that 
only about 40% of APCs will be needed in the future for specific 
patients requiring HLA/HPA-matched platelets. However, one 
might speculate that the target 60% instead of 40% includes an 
ample safety margin to avoid risks on the side of the apheresis 
donor pool [8, 9].
To capture the consequences of changes in PPC/APC produc-
tion in Germany we designed a comprehensive model. The base 
case describes the current situation of PPC/APC production in 
Germany with a proportion of 61.5% APCs in 2013 [13]. For the 
production of 222,228 buffy coat-derived PPCs, a total of 19.2% of 
the annual WBDs are used. During production of buffy coats for 
PPCs red blood cells are lost. In total, the calculated losses amount 
to 1–2% of all RBCCs which were donated that year. In scenario 
calculations we varied the proportion of APC/PPC provision. In 
case the proportion of APCs is lowered to 40% as has been recom-
mended for the UK, the estimated loss of annual RBCCs during the 
production process of the 60% PPCs will increase up to 3%. This 
corresponds to an estimated number of more than 130,000 RBCCs 
lost annually, 1.6 times as much as in the base case. Calculations 
with the assumption of stable decay rates at the producer result in 
an increase of PC decay from 46,218 PCs (8.0%) for the base case to 
54,189 PCs (9.4%) with 60% PPCs.
Development of the Supply with WBDs
In Germany, WBDs decreased from 2011 to 2012 by 3.2% and 
from 2012 to 2013 by 2.9% [13]. A concomitant reduction in RBCC 
consumption from 2010 to 2011 by 1.3%, from 2011 to 2012 by 
2.2%, and from 2012 to 2013 by 6.5% was observed, presumably 
due to a more restrictive use of blood products and the introduc-
tion of the concept of ‘patient blood management’ [22]. Simultane-
ously, the number of WBDs per 1,000 inhabitants has decreased 
from 2011 to 2013 from 61 to 57, whereas the number of apheresis 
donations per 1,000 inhabitants still increased from 2011 to 2013 
from 33 to 34 [13]. This indicates, in accordance with the predicted 
donor development in Germany in the upcoming years, that the 
restrictive use in blood products might not be sufficient to balance 
the decrease in WBDs and the subsequent decrease in the produc-
tion of RBCCs in the future [12]. Expected demographic changes 
will lead to an aging population with a decreasing number of do-
nors while an increasing number of cancer cases will increase the 
demand for blood products, especially PCs [23–25]. The shrinking 
process in the donor population has been predicted to accelerate, 
in particular after 2015 [23].
Supply with HLA/HPA-Typed Platelets
HLA/HPA-typed apheresis concentrates are indicated for trans-
fusion refractory patients due to HLA antibodies and FNAIT [2, 3, 
6, 16, 17]. The shift to PPCs will lead to shrinkage of the HLA/
HPA-typed apheresis donor pool. This will be due to a decreased 
demand of apheresis donations and reduced recruitment of new 
apheresis donors. Currently, each apheresis center caring for these 
patients has built up a sufficiently large pool of donors to allow for 
timely delivery of matched APCs even for rare constellations. 
However, the number of apheresis donors needed to supply imme-
diate HLA-matched APCs has not been defined. Therefore, it has 
not been incorporated into the model. It is obvious that substantial 
problems in achieving the supply of matched APCs can occur.
Major Use of Platelet Transfusions in Hemato-Oncological 
Patients
Few studies have been published so far on the epidemiology of 
PC use in terms of distribution of PCs to different patient groups 
evaluating the need for PPCs or APCs, [26]. One German single-
center study showed that 56.6% of all PC transfusions (data for 
Table 3. Scenarios for different proportions of PPCs produced*
Percent PPCs of total PCs produced 10 20 30 40 50 60 70 80 90 100
Percent of annual WBDs used for  
production of PPCs
5 10 15 20 25 30 35 40 45 50








































Estimated percentage of annual RBCs  
lost, %
0.25–0.5 0.5–1.0 0.75–1.5 1,0–2.0 1,25–2.5 1.5–3.0 1.75–3.5 2.0–4.0 2.25–4.5 2.5–5.0
Decay at the producer: number of PCs 35,649 39,357 43,066 46,774 50,481 54,189 57,898 61,606 65,314 69,022
*In Germany, total WBDs in 2013 were 4,631,290 used for the production of 4,371,743 RBCs (94.4% of WBDs). Total production of PCs was 577,593 units [13].  
It is assumed that losses of erythrocytes due to production of buffy coats for PPC production from WBDs amount to 5–10% of the WBDs used [14]. The number 
of WBDs lost annually, as well as the corresponding number of RBCs otherwise produced from these WBDs can be calculated. As a function of the proportion of 
PPCs produced the percentage of WBDs used for production of PPCs changes. As a result also the estimated number and percentage of annual RBCs lost due to 
production of buffy coat derived PPCs are changed. Due to different rates of decay at the producer for PPCs and APCs the overall rate of platelet concentrate 
decay changes as well (table 2).
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2011, apheresis only) were given to patients over 50 years of age. 
Hemato-oncological patients comprised 37.1% of all cases and re-
ceived 50.9% of transfused units of PCs [27]. A study on PC use in 
the North of England in 2012 showed similarly that 60.5% of PC 
transfusions were given to hemato-oncological patients. The me-
dian age of PC recipients was 57 years [28]. In our hospital, a total 
of 10,071 APCs were transfused in 2014 to 1,684 patients, thereof 
5,613 APCs to 538 hemato-oncological patients (data on file, De-
partment of Transfusion Medicine, Cell Therapeutics and Hemo-
staseology, University Hospital of Munich, ). A survey of the PEI 
regarding indications for PC transfusions in 2011 and 2012 showed 
that approximately 75% of all PCs were transfused in hemato-on-
cological departments including pediatric divisions [16, 17].
Immunosuppressed hemato-oncological patients require fre-
quent PC transfusions and are prone to infections, allergic reac-
tions, and alloimmunization [6]. Therefore, special subgroups of 
these patients, e.g. multitransfused leukemia patients or allogeneic 
hematopoietic stem cell transplantation recipients, might benefit 
from the use of APCs because of the lower exposure to antigens 
from a single donor with a possibly lower risk of allergic reactions 
and alloimmunization. However, prospective comparative studies 
on the use of APCs and PPCs in subgroups of these patients are 
currently rare or not available [5, 29]. 
Limitations of the Model and Future Challenges
The model was designed in a conservative way to avoid overes-
timations. Model assumptions were based on the scarce data pub-
lished due to the lack of comprehensive evidence-based data. In 
consequence the following limitations arise and should be taken 
into consideration when interpreting the presented results: It was 
assumed that 4 WBDs are needed to obtain 1 PPC, even though for 
a certain percentage of the PPCs 5 or 6 buffy coats may be pooled. 
Due to the lack of representative information on the real number 
of WBDs used in Germany for the production of PPCs it might be 
possible, that the amount of red blood cells lost is higher than cal-
culated in the model. Due to a lack of data, it was assumed on the 
basis of a published estimation that the loss of erythrocytes 
amounts to 5–10% of the WBDs used for PPC production. There-
fore, the model can only give a range of the corresponding WBDs 
and RBCCs lost annually. The real number might be even higher. 
The decay rate at the producer for PPCs and APCs was assumed to 
remain stable. However, it might as well be the case that decay rates 
of PPCs decrease and decay rates of APCs increase when the pro-
portion of PPCs to APCs changes to a preponderance of PPCs. Sci-
entific papers have been published in the literature regarding risks 
of PPCs and APCs for recipients and donors [11, 15–17, 19–21]. 
The various safety aspects were not considered in the model. A 
comprehensive model should include data on efficacy and effec-
tiveness of PPCs and APCs. However, so far no prospective rand-
omized studies on clinical efficacy or comparative observational 
studies on the effectiveness of buffy coat PPCs and single-donor 
APCs have been published.
Conclusion
In conclusion, model calculations were provided to increase 
transparency on the sensitiveness in the context of blood produc-
tion and blood supply. The impact of shifts in the production of 
PPCs and APCs on blood product supply in Germany was chosen 
as an example. To predict the optimal proportion of pooled PCs 
and single-donor apheresis PCs, reliable data are needed on PPC 
production, loss of erythrocytes, future PC demand, donor availa-
bility and future donations, donor pool required for HLA/HPA 
typed apheresis platelets, decay of pooled PCs and apheresis PCs, 
and demand of single-donor apheresis PCs for specific patients.
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